Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide.

Gross DA, Leborgne C, Chappert P, Masurier C, Leboeuf M, Monteilhet V, Boutin S, Lemonnier FA, Davoust J, Kichler A.

Sci Rep. 2019 Mar 8;9(1):3937. doi: 10.1038/s41598-019-40594-7.


Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.

Leborgne C, Latournerie V, Boutin S, Desgue D, Quéré A, Pignot E, Collaud F, Charles S, Simon Sola M, Masat E, Jouen F, Boyer O, Masurier C, Mingozzi F, Veron P.

Cell Immunol. 2019 Aug;342:103780. doi: 10.1016/j.cellimm.2018.03.004. Epub 2018 Mar 16.


Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.

Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, Allais M, François V, Dutilleul M, Malerba A, Koo T, Thibaut JL, Matot B, Devaux M, Le Duff J, Deschamps JY, Barthelemy I, Blot S, Testault I, Wahbi K, Ederhy S, Martin S, Veron P, Georger C, Athanasopoulos T, Masurier C, Mingozzi F, Carlier P, Gjata B, Hogrel JY, Adjali O, Mavilio F, Voit T, Moullier P, Dickson G.

Nat Commun. 2017 Jul 25;8:16105. doi: 10.1038/ncomms16105.


Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.

Le Guiner C, Montus M, Servais L, Cherel Y, Francois V, Thibaud JL, Wary C, Matot B, Larcher T, Guigand L, Dutilleul M, Domenger C, Allais M, Beuvin M, Moraux A, Le Duff J, Devaux M, Jaulin N, Guilbaud M, Latournerie V, Veron P, Boutin S, Leborgne C, Desgue D, Deschamps JY, Moullec S, Fromes Y, Vulin A, Smith RH, Laroudie N, Barnay-Toutain F, Rivière C, Bucher S, Le TH, Delaunay N, Gasmi M, Kotin RM, Bonne G, Adjali O, Masurier C, Hogrel JY, Carlier P, Moullier P, Voit T.

Mol Ther. 2014 Nov;22(11):1923-35. doi: 10.1038/mt.2014.151. Epub 2014 Aug 4.


Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.

Childers MK, Joubert R, Poulard K, Moal C, Grange RW, Doering JA, Lawlor MW, Rider BE, Jamet T, Danièle N, Martin S, Rivière C, Soker T, Hammer C, Van Wittenberghe L, Lockard M, Guan X, Goddard M, Mitchell E, Barber J, Williams JK, Mack DL, Furth ME, Vignaud A, Masurier C, Mavilio F, Moullier P, Beggs AH, Buj-Bello A.

Sci Transl Med. 2014 Jan 22;6(220):220ra10. doi: 10.1126/scitranslmed.3007523.


Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.

Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, Masurier C.

J Immunol. 2012 Jun 15;188(12):6418-24. doi: 10.4049/jimmunol.1200620. Epub 2012 May 16.


A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.

Herson S, Hentati F, Rigolet A, Behin A, Romero NB, Leturcq F, Laforêt P, Maisonobe T, Amouri R, Haddad H, Audit M, Montus M, Masurier C, Gjata B, Georger C, Cheraï M, Carlier P, Hogrel JY, Herson A, Allenbach Y, Lemoine FM, Klatzmann D, Sweeney HL, Mulligan RC, Eymard B, Caizergues D, Voït T, Benveniste O.

Brain. 2012 Feb;135(Pt 2):483-92. doi: 10.1093/brain/awr342. Epub 2012 Jan 11.


A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.

Monteilhet V, Saheb S, Boutin S, Leborgne C, Veron P, Montus MF, Moullier P, Benveniste O, Masurier C.

Mol Ther. 2011 Nov;19(11):2084-91. doi: 10.1038/mt.2011.108. Epub 2011 May 31.


Polymers for improving the in vivo transduction efficiency of AAV2 vectors.

Moulay G, Boutin S, Masurier C, Scherman D, Kichler A.

PLoS One. 2010 Dec 28;5(12):e15576. doi: 10.1371/journal.pone.0015576.


Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer.

Moulay G, Masurier C, Bigey P, Scherman D, Kichler A.

Gene Ther. 2010 Nov;17(11):1400-10. doi: 10.1038/gt.2010.94. Epub 2010 Jul 1.


Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C.

Hum Gene Ther. 2010 Jun;21(6):704-12. doi: 10.1089/hum.2009.182.


Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation.

Veron P, Boutin S, Martin S, Chaperot L, Plumas J, Davoust J, Masurier C.

J Transl Med. 2009 Jan 27;7:10. doi: 10.1186/1479-5876-7-10.


Myosin binding protein C positioned to play a key role in regulation of muscle contraction: structure and interactions of domain C1.

Ababou A, Rostkova E, Mistry S, Le Masurier C, Gautel M, Pfuhl M.

J Mol Biol. 2008 Dec 19;384(3):615-30. doi: 10.1016/j.jmb.2008.09.065. Epub 2008 Oct 7.


Enhanced lentiviral transduction of monocyte-derived dendritic cells in the presence of conditioned medium from dying monocytes.

Masurier C, Boutin S, Veron P, Bernard J, Danos O, Davoust J.

Hum Gene Ther. 2007 Feb;18(2):161-70.


Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2.

Veron P, Allo V, Rivière C, Bernard J, Douar AM, Masurier C.

J Virol. 2007 May;81(10):5385-94. Epub 2007 Feb 21.


BCR/ABL promotes dendritic cell-mediated natural killer cell activation.

Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, Zitvogel L.

Cancer Res. 2005 Jul 15;65(14):6409-17.


Similar immune responses and antitumor effects of murine dendritic cells loaded with either exogenous or endogenous-synthesized protein.

Lacave R, Masurier C, Guigon M, Lemoine FM, Klatzmann D, Colombo BM.

Int J Oncol. 2003 Dec;23(6):1747-53.


[Role of dendritic cells in the modulation of innate effectors of immunity].

Terme M, Masurier C, Fernandez N, Lacassagne MN, Marolleau JP, Zitvogel L.

Pathol Biol (Paris). 2001 Jul;49(6):475-7. Review. French.


Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.

Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L.

Nat Med. 2001 Mar;7(3):297-303.


Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia.

Colombo BM, Lacave R, Pioche-Durieu C, Masurier C, Lemoine FM, Guigon M, Klatzmann D.

Immunology. 2000 Jan;99(1):8-15.


Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice.

Masurier C, Salomon B, Guettari N, Pioche C, Lachapelle F, Guigon M, Klatzmann D.

J Virol. 1998 Oct;72(10):7822-9.


Three populations of mouse lymph node dendritic cells with different origins and dynamics.

Salomon B, Cohen JL, Masurier C, Klatzmann D.

J Immunol. 1998 Jan 15;160(2):708-17.


Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats.

Michel O, Heudes D, Lamarre I, Masurier C, Lavau M, Bariety J, Chevalier J.

Kidney Int. 1997 Dec;52(6):1532-42.


The role of dendritic cells in the transport of HIV to lymph nodes analysed in mouse.

Masurier C, Guettari N, Pioche C, Lacave R, Salomon B, Lachapelle F, Klatzmann D, Guigon M.

Adv Exp Med Biol. 1997;417:411-4. No abstract available.


[Approach of cellular mechanisms of glomerulosclerosis in a model of accelerated aging the obese Zucker rat].

Chevalier J, Masurier C, Lavaud S, Michel O, Bariety J.

C R Seances Soc Biol Fil. 1995;189(6):987-1007. Review. French.


[Plasma fibronectin in acute septic respiratory distress syndromes].

Fourrier F, Chopin C, Steenhouwer F, Masurier C.

Presse Med. 1983 Jun 11;12(25):1611. French. No abstract available.


Supplemental Content

Loading ...
Support Center